Teva (TEVA) Q3 FY25 earnings call

Teva delivered its eleventh consecutive quarter of growth, primarily fueled by its innovative product portfolio, which saw significant year-over-year expansion. The company reaffirmed its 2027 financial targets, including mid-single-digit revenue growth and a 30% operating margin, supported by ongoing cost transformation programs and a strengthening balance sheet. While the TAPI divestiture faced a setback, management is re-initiating the sale process, emphasizing its non-strategic nature to the 'pivot to growth' strategy.